NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Arsenal Capital Partners, a leading New York-based private equity firm that invests in middle market healthcare and specialty industrial companies, announced today the acquisition of Certara, the leading provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.Certara provides highly specialized and integrated solutions which consist of computer-based models supported by leading scientific consulting services and which span the discovery, pre-clinical and clinical stages of drug development. Certara's solutions provide clients with significant reductions in the time and expense of bringing new drugs to market by enabling data-driven decisions which lead to more precisely designed studies with less risk of failure and improved subject safety– a benefit in the highly-regulated and increasingly costly research and development environment.
Stephen McLean, a Partner at Arsenal and Co-Head of the firm's Healthcare Group, said, "We are delighted to invest in this exciting company which is making such an important contribution to improving the productivity of the drug development process. The average cost today of researching and developing a new drug is over $1.5 billion and takes 10-15 years. This is clearly inconsistent with the imperative of reducing the costs of global healthcare and Certara will make a difference."
Dr. James Rothman, a recipient of the 2013 Nobel Prize in Physiology or Medicine, who evaluated the Certara acquisition in his role in Arsenal Capital Partners' Healthcare Group, said Arsenal was interested in the acquisition because of Certara's ability to increase both the effectiveness and efficiency of the drug development process. "Model-based drug development is allowing pharmaceutic
|SOURCE Arsenal Capital Partners|
Copyright©2012 PR Newswire.
All rights reserved